- Investigator, Clinical Genetics Branch
Dr. Achatz received her medical degree at Faculdade de Medicina do ABC, São Paulo, Brazil, and completed residency training in Medical Genetics. She received a Master´s Degree in Science (Oncology) at Fundação Antonio Prudente, São Paulo, and completed her doctorate at the Universidade de São Paulo. Dr. Achatz joined the Department of Oncogenetics at A.C. Camargo Cancer Center as a part of Medical Staff in 2003. In 2004, she completed a fellowship at the International Agency for Research on Cancer in Lyon, France, as Visiting Scientist on Li-Fraumeni syndrome (LFS) studies. In 2005, she became Director of the Department of Oncogenetics at A.C. Camargo Cancer Center, the main referral center for Oncogenetics in Brazil. Dr. Achatz was nominated as coordinator of the Oncogenetics Department at the Brazilian Society of Medical Genetics in 2009. In 2010, she became the Head of the Laboratory of Molecular Oncogenetics at the International Center for Research, A.C. Camargo Cancer Center. In 2016, she was appointed as a tenure-track investigator in the Division and head of the NCI LFS Study.
Articles2
- (2020). Comprehensive germline mutation analysis and clinical profile in a large cohort of Brazilian xeroderma pigmentosum patients. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY.
- (2020). MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers. Cancer Genetics. 240, 54-58.
Academic Articles84
- (2020). Suggested application of HER2+breast tumor phenotype for germlineTP53variant classification within ACMG/AMP guidelines. HUMAN MUTATION. 41(9), 1555-1562.
- (2020). Comprehensive germline mutation analysis and clinical profile in a large cohort of Brazilian xeroderma pigmentosum patients. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY.
- (2020). Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 29(5), 927-935.